Back to top

gene-editing: Archive

Neena Mishra

Should You Buy Beaten-Down Biotech Stocks & ETFs?

We highlight 4 ETFs that have started rebounding after a brutal sell-off

AMGNNegative Net Change GILDNegative Net Change VRTXPositive Net Change IBBPositive Net Change TDOCNegative Net Change XBIPositive Net Change CRSPNegative Net Change ARKGPositive Net Change IBBQPositive Net Change

Bryan Hayes

The Overlooked Difference in June's Inflation Report

Today's reaction to a high CPI print is the opposite of what we saw last month.

VRTXPositive Net Change IBBPositive Net Change

Zacks Equity Research

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

ALKSPositive Net Change ABEOPositive Net Change AVROPositive Net Change

Zacks Equity Research

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

ALKSPositive Net Change VRTXPositive Net Change CRSPNegative Net Change SESNPositive Net Change

Zacks Equity Research

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

REGNPositive Net Change ALKSPositive Net Change FOLDPositive Net Change NTLANegative Net Change